HL2351 CAPS Phase II Study

Summary

This is an open label, single arm trial to evaluate the efficacy, safety, and pharmacokinetics of HL2351 in patients with cryopyrin associated periodic syndromes (CAPS).

Timeline

Start

2015-10

Primary completion

2017-05

Completion

2019-01

Drugs

Indications